SEHK:6181
SEHK:6181Luxury

3 Asian Growth Companies Insiders Own With Up To 37% Earnings Growth

As global markets navigate a complex landscape marked by fluctuating consumer sentiment and evolving trade dynamics, Asian markets continue to capture investor interest with their growth potential and strategic positioning. In this environment, companies exhibiting strong insider ownership can be particularly appealing, as such ownership often signals confidence in the company's future prospects and alignment with shareholder interests.
SEHK:1318
SEHK:1318Personal Products

Asian Stocks Estimated To Be Up To 38.1% Below Intrinsic Value

As global markets face challenges such as AI valuation concerns and economic uncertainties, Asian stocks have shown resilience with some indices reaching new highs. In this environment, identifying undervalued stocks becomes crucial, as they may offer potential opportunities for investors seeking to capitalize on discrepancies between market price and intrinsic value.
SEHK:340
SEHK:340Metals and Mining

Asian Penny Stocks To Watch In November 2025

Amid the evolving global economic landscape, Asian markets have shown resilience, with Chinese indices experiencing gains due to easing trade tensions. In this context, penny stocks—often smaller or newer companies—remain a noteworthy investment area despite their historical connotations. These stocks can offer a unique blend of affordability and growth potential when backed by strong financials, making them intriguing options for investors seeking opportunities beyond mainstream equities.
SEHK:1109
SEHK:1109Real Estate

How Investors May Respond To China Resources Land (SEHK:1109) After Hong Kong’s Economic Rally and Trade Truce

In recent days, Hong Kong’s economy has shown resilience with 3.8% GDP growth and rising retail sales, providing support to key developers like China Resources Land. A recent U.S.-China trade truce and tariff reductions offer further relief to companies involved in cross-border property markets, even as China faces manufacturing headwinds. To assess what this means for China Resources Land, we’ll explore how Hong Kong’s strong economic performance influences the company’s investment...
SEHK:388
SEHK:388Capital Markets

Hong Kong Exchanges and Clearing (SEHK:388): Assessing Valuation After Strong Earnings Growth

Hong Kong Exchanges and Clearing (SEHK:388) just released its latest earnings, showing a clear jump in both revenue and net income for the third quarter and the year to date, compared to last year. See our latest analysis for Hong Kong Exchanges and Clearing. Strong results have helped drive Hong Kong Exchanges and Clearing’s share price up by more than 50% year-to-date. Its total shareholder return over the past year reached an impressive 37%. That momentum reflects renewed optimism...
SEHK:1199
SEHK:1199Infrastructure

COSCO SHIPPING Ports (SEHK:1199): Valuation Insights Following Strong Nine-Month Earnings Growth

COSCO SHIPPING Ports (SEHK:1199) released its third quarter and nine-month earnings, drawing attention for showing higher sales and net income compared to last year. Investors are likely watching to see how these stronger results play out. See our latest analysis for COSCO SHIPPING Ports. The recent bump in nine-month earnings has come as COSCO SHIPPING Ports' share price has gained steady ground, up 29.3% year-to-date and closing at $5.91. With a 43.6% total return for the year, the stock's...
SEHK:9995
SEHK:9995Biotechs

RemeGen (SEHK:9995) Valuation in Focus After Sales Growth and Positive Telitacicept Trial Results

RemeGen (SEHK:9995) just posted stronger sales numbers and trimmed its net loss for the first nine months of 2025. At the same time, new study results for its telitacicept drug are bolstering investor confidence. See our latest analysis for RemeGen. RemeGen’s stock has been volatile but delivered impressive gains for investors this year, with the share price up 524% year-to-date and a one-year total shareholder return of nearly 340%. After spiking sharply on optimism about its clinical...
SEHK:9966
SEHK:9966Biotechs

Can Alphamab Oncology’s (SEHK:9966) FDA Fast Track Milestone Reshape Its Competitive Position in Oncology?

Alphamab Oncology recently announced that its drug candidate JSKN003 has received Fast Track Designation from the U.S. FDA for the treatment of platinum-resistant recurrent epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube cancer, without restriction by HER2 expression. This regulatory milestone builds on promising international clinical trial data and highlights momentum in Alphamab's pipeline of antibody-based oncology therapies. We'll explore how the U.S. FDA's Fast...
SEHK:2669
SEHK:2669Real Estate

Could Management Changes at China Overseas Property (SEHK:2669) Shift the Company’s Long-Term Strategic Focus?

China Overseas Property Holdings Limited announced that, following a board meeting on October 28, 2025, Mr. Pang Jinying resigned from his roles as Executive Director, Vice President, and alternate to the authorised representative due to a realignment of work duties. This departure marks a significant leadership transition and raises important considerations about continuity in management and overall corporate governance. We will assess how this key executive change could influence investor...
SEHK:9969
SEHK:9969Biotechs

What InnoCare Pharma (SEHK:9969)'s New B7-H3 ADC Trial and Pediatric Data Reveal for Shareholders

InnoCare Pharma recently announced two important milestones: the first patient was dosed in a Chinese clinical trial for its novel B7-H3 targeted ADC (ICP-B794), and encouraging new phase I/II clinical data on zurletrectinib for pediatric and adolescent solid tumors was shared at an international oncology congress. Of particular note, ICP-B794 addresses a significant unmet need as there are currently no B7-H3 targeted therapies approved for marketing globally, highlighting InnoCare’s focus...
SEHK:1072
SEHK:1072Electrical

Why Dongfang Electric (SEHK:1072) Is Up 9.0% After Posting Higher Sales and Net Income for Q3

Earlier this month, Dongfang Electric Corporation Limited released earnings results for the nine months ended September 30, 2025, reporting sales of CNY 54.74 billion and net income of CNY 2.97 billion, both higher than the same period last year. The company also announced plans to amend its Articles of Association, with changes pending shareholder approval at an upcoming extraordinary general meeting. We'll explore how Dongfang Electric's strong earnings growth reinforces its investment...
SEHK:175
SEHK:175Auto

Surging October Sales Could Be a Game Changer for Geely Automobile Holdings (SEHK:175)

Geely Automobile Holdings reported unaudited group vehicle sales for October 2025, delivering 307,133 units for the month and 2.48 million units year-to-date, both substantially higher than the corresponding periods last year. This sharp rise in sales volume highlights strong demand and could be seen as a reflection of Geely's expansion efforts and product appeal in an increasingly competitive market. We'll examine how Geely's record monthly and year-to-date sales performance informs its...
SEHK:1672
SEHK:1672Biotechs

Ascletis Pharma (SEHK:1672) Is Up 5.5% After Revealing Promising Obesity Drug Updates at ObesityWeek 2025 Has The Bull Case Changed?

Ascletis Pharma announced positive Phase Ib results for its ASC30 oral and subcutaneous formulations, showing notable placebo-adjusted mean body weight reduction, a favorable safety profile, and ultra-long half-lives supporting both monthly and quarterly dosing, with these updates presented recently at ObesityWeek 2025. The company also unveiled new preclinical results where a combination of ASC47 and ASC31 outperformed monotherapies in promoting both weight and fat loss, and advanced its...